|
|
 |
|
Viewing report
|
|
|
|
Company Financials: Orexigen Therapeutics, Inc.
Datamonitor, Jan 2010
The Company Financials offers insights into the financial performance of the company over last five years for about 1000 leading global companies. The datapack covers wealth of financial information relating to income statement, balance sheet, and cash flow statements. .
Scope
- Contains five years data on income statement, balance sheet, cash flows and other financials in the reported currency and its US Dollar translation
- Provides key ratios
- Includes information on revenue distribution by business segments and geographies
Highlights of this title
Orexigen Therapeutics is engaged in developing pharmaceutical product candidates for the treatment of central nervous system (CNS), disorders, including obesity.
Key reasons to purchase this title
- Access important financial information and analysis on the company in a single datapack
- Understand the financial evolution of the company over the last five years
- Build the periodic assessment of the company's performance for five year adjusted financial data along with key ratios and market capitalization
Customers who bought this item also bought
Product Profiles: Obesity - Pipeline stalls as regulatory requirements escalate
Obesity Drug Discoveries: what the future holds
Hot Topics: Obesity - Three Complete Response Letters and one Advisory Committee meeting
Obesity Drug Discoveries: what the future holds + Obesity Tracker
Obesity - The $11 billion market that never was
R&D Trends: Obesity - 2006-2011: Obesity's Lean Years
Hot Topics: Obesity - The US FDA and cardiovascular risk analysis: the AdComm Cometh
Clinical Operations: Benchmarking Per-Patient Trial Costs, Staffing and Adaptive Design
Clinical Trial Patient Recruitment: Accelerate Enrollment, Increase Retention and Reduce Costs
Sustained Release Injectables: Evolving Formulations, Improving Dosing Regimens
|
|
|
|
